Reverse Remodeling of NIDCM of diagnosis, and (3) no significant coronary artery disease defined as >50% diameter narrowing in any of the major coronary arteries or their branches. Patients with infiltrative or inflammatory heart diseases such as cardiac amyloidosis, sarcoidosis, and acute myocarditis were excluded. Patients with coexisting significant disease that decreased life expectancy or organic heart valve disease were also excluded.
The study subjects enrolled in the HF database were evaluated and managed according to the common clinical pathway for HF patients established at this institute. Briefly, after admission, a comprehensive clinical history was obtained and a physical examination was performed. Blood samples were obtained for laboratory tests including measurement of the NTproBNP level (Roche Diagnostics, Indianapolis, IN, USA), and 12-lead ECG, standard chest radiography, and echocardiographic evaluation were performed routinely. Coronary angiography and/or coronary computed tomography angiography were also performed if not evaluated previously. The study patients were treated with β-blockers and RAS inhibitors in addition to diuretics and digitalis according to the HF treatment guidelines unless clinically contraindicated. 10 The study protocol was approved by the institutional review board and written informed consent was waived.
Echocardiographic Evaluation
Comprehensive 2-dimensional and Doppler echocardiographic evaluation was performed in all patients according to the guidelines of the American Society of Echocardiography. 11 The LVEDD and LV end-systolic dimension (LVESD) were measured using M-mode, and the LVEF was calculated using the area-length method or biplane Simpson's method in patients with regional wall motion abnormality. The transmitral early (E) and late (A) velocities, E wave deceleration time, and E to A ratio were measured. 12 Mitral early diastolic annular (e′) velocity was measured at the medial annulus, and the E to e′ ratio was calculated. The LV dimension and left atrial volume were normalized for body surface area.
Evaluation of LVRR and Midterm NT-proBNP Level
The clinical follow-up and laboratory tests, including measurement of NT-proBNP level and echocardiography, were repeated after tailored medical treatment at the midterm follow-up, which was defined as the follow-up visit 6 months to 2 years after the baseline evaluation. LVRR was confirmed if the following criteria were met in the midterm follow-up evaluation: (1) an absolute increase in LVEF ≥20% or ≥10% in patients with a follow-up LVEF ≥50% and (2) a decrease in the LVEDD index ≥10% or an LVEDD index ≤33 mm/m 2 . 13 If multiple evaluations were performed during the midterm follow-up period, tests revealing LVRR and/or those performed at a relative midpoint of the period were chosen for the analysis.
Clinical Events and Relapsed HF in Patients With LVRR
The combined clinical events of cardiovascular death, heart transplantation (HTx), and hospitalization for HF were monitored during the follow-up by the attending physicians and through chart reviews. For study patients who were not evaluated during the follow-up, clinical events were assessed through a direct telephone interview and information about survival status was obtained from the national insurance database. After the evaluation of LVRR and midterm NT-proBNP level, the study patients were classified into 4 groups according to the LVRR and midterm NT-proBNP level: group I included patients with LVRR and a midterm NT-proBNP level <500 pg/ml, group II included patients with LVRR and midterm NT-proB-NP level ≥500 pg/ml, group III included those without LVRR and midterm NT-proBNP level <500 pg/ml, and group IV included those without LVRR and midterm NT-proBNP level ≥500 pg/ml. Relapsed HF after LVRR was defined as recurrence of HF symptoms and a LVEF <50% together with a decrease >10% from the value at the midterm evaluation.
Statistical Analysis
Continuous data are presented as mean ± SD and/or interquartile range, and categorical data as numbers and percentages (%) . Differences between groups were tested using Student's t-test for continuous data and chi-square test (or Fisher's exact test where appropriate) for categorical variables. Paired t-tests were used to compare the values between the baseline and midterm follow-up. To evaluate the predictors of LVRR from the baseline characteristics, univariate analysis included all relevant clinical or laboratory parameters of the patients at enrollment. In the multivariate logistic regression analysis, a backward stepwise algorithm was applied to the list of selected parameters with a P value <0.10 from the univariate analysis. Survival data were analyzed using the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox regression analysis was used to identify independent predictors of clinical events from the clinical and echocardiographic parameters. To evaluate the effect of LVRR and midterm NT-proB-NP level on the long-term event-free survival, landmark analysis was performed from the time of the midterm evaluation.
Significance was defined as P<0.05.
Results

Clinical Characteristics at Baseline
Among the 329 patients who were evaluated at the time of admission, 62 (19%) did not have the midterm follow-up evaluation and 14 (4%) had combined clinical events (7 cardiac deaths, 7 HTx) by the midterm follow-up (Figure 1) . No patient had undergone cardiac resynchronization therapy prior to the midterm evaluation. The clinical and laboratory findings of the study patients (n=253, 77%) who were evaluated at both the baseline and midterm follow-up are summarized in Table 1 . Underlying causes of HF were idiopathic dilated cardiomyopathy in 202 patients (80%), followed by alcohol-related in 25 (9.9%), hypertension-related in 14 (5.5%), and chemotherapy-related in 12 (4.7%). The follow-up period until midterm evaluation was 16±7 months. Patients who had a clinical event or cardiac death and/or HTx before the midterm followup had more severe and advanced disease compared with those who did not ( Table S1 ). Most of the clinical and laboratory features of the patients who were not evaluated at the midterm follow-up did not differ significantly from those of the study population. After the midterm evaluation, the study patients were evaluated for combined clinical events, with a mean follow-up duration of 29±22 months. 
Factors Related to LVRR at the Midterm Follow-up
Factors Related to Overall Clinical Events and Survival
The results of the multivariate Cox regression analysis for the prediction of overall combined clinical events, HF hospitalization, cardiac death, and HTx from the baseline data are shown in Table 5 . The following variables were independent predictors of the combined events of HF hospitalization, cardiac death, and HTx: baseline SBP (for every 10 mmHg increase, hazard ratio [HR] 0.90, 95% CI 0.81-0.99; P=0.023), QRS duration >120 ms (HR 2.30, 95% CI 1.55-3.43; P<0.001), log NT-proBNP level measured at baseline (HR 1.93, 95% CI 1.36-2.75; P<0.001), and use of a β-blocker (HR 0.58, 95% CI 0.39-0.85; P=0.005). The following variables were independent predictors of cardiac death and/or HTx: baseline SBP 
Clinical Events After the Midterm Evaluation of LVRR and NT-proBNP Level
The event rates of the patients with LVRR were compared with those of the other patients and are shown in Table 6 . LVRR was associated with lower rates of HF hospitalization (6.2% vs. 34.6%; P<0.001), cardiac death (0% vs. 16.7%; P<0.001), and HTx (0% vs. 5.8%; P=0.014, Table 6 ). The 
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event-free survival rates of the study population classified according to LVRR and the midterm NT-proBNP level are shown in Figure 2 . Group I patients had a significantly better longterm prognosis, and group IV patients had poor long-term prognosis compared with the other groups (P<0.001). The multivariate Cox regression model analysis using landmark survival analysis after the midterm follow-up included age, sex, QRS duration >120 ms, chronic renal failure, and atrial fibrillation as covariates. The multivariate Cox regression showed that the following variables were independently related to the longterm combined clinical events after the midterm follow-up: LVRR (HR 0.16, 95% CI 0.07-0.38; P<0.001), midterm log NT-proBNP level (HR 2.16, 95% CI 1.53-3.04; P<0.001), and continuous use of a β-blocker at the midterm follow-up (HR 0.56, 95% CI 0.34-0.92; P=0.023, Figure 2 ). In the patients who developed LVRR, only 6 required readmission because of resuscitated sudden cardiac death (n=1), syncope with HF medication (n=1), and acute decompensated HF (n=4). Among 97 patients with LVRR, 10 (10%) patients had a relapse of HF. Except for the continuous use of a β-blocker at the midterm follow-up, the midterm clinical and echocardiographic variables were not significantly different between the patients with and without recurrent HF. At the midterm follow-up, patients who developed relapsed HF after LVRR had a lower rate of use of β-blockers (50.0% vs. 83.9%; P=0.018).
Discussion
In this study of patients with NIDCM, higher systolic blood pressure (SBP), QRS duration <120 ms, small LVESD index, and the use of a β-blocker were independently related to LVRR at the midterm follow-up. In these patients, LVRR and lower NT-proBNP level at the midterm follow-up and continuous use of a β-blocker were related to a good long-term prognosis up to 7 years (mean follow-up duration of 29±22 months) after the midterm follow-up.
Factors Related to LVRR at the Midterm Follow-up and Long-Term Prognosis of NIDCM
Neurohormonal blocking agents, especially β-blockers, in addition to RAS inhibitors, have been shown to be effective for LV remodeling in NIDCM. 14,15 Beta-blockers are now used widely, and LVRR has become a surrogate marker of successful treatment. A recent analysis of 53 patients with NIDCM showed that SBP, QRS duration, being female, and having diabetes are related to LVRR. 16 Another study also reported that higher SBP and the absence of LBBB are the most sensitive independent predictors of LVRR. 8 This latter study was similar to ours in the number of study patients, the hospital settings, and incidence of LVRR. Prolonged QRS duration and a larger LVESD index may be related to structural changes in the conduction system and to more severe LV dysfunction in some respects. Together with a previous study, our results suggest that prompt and early application of neurohormonal blocking agents before the onset of definite structural and functional LV changes is crucial to LVRR. Systolic blood pressure is a well-known prognostic factor in patients with HF, and hypertensive HF usually improves as a result of adequate afterload reduction followed by a dramatic improvement in LV function. 17 Thus, our study results confirm that LVRR in NIDCM is observed more frequently in patients with higher SBP and normal QRS duration, factors that are also related to a favorable prognosis in these patients.
Interestingly, other prognostic factors such as serum sodium and NT-proBNP levels, which were also related to overall long-term prognosis in our study, were not related to LVRR at the midterm follow-up. Furthermore, LV with lower EF was related to reverse remodeling in our patient population. We speculate that the serum sodium and NT-proBNP levels may represent the extent of a compensatory response to HF, whereas the QRS duration may be related to the severity of the struc- 
Clinical Events After the Midterm Evaluation of LVRR and NT-proBNP Level
LVRR was recently reported to be related to the long-term prognosis of NIDCM. 7, 8 A study of 43 patients with NIDCM reported a significant improvement in survival rate in the patients with LVRR. 8 Another study demonstrated that a prognostic model that combines baseline and midterm follow-up data predicts the prognosis with improved accuracy. 7 In the current study, patients with LVRR and lower midterm NTproBNP level showed excellent long-term prognosis (Figure 2) , which suggests that the structural and functional monitoring of HF is important for identifying the future risk of adverse events. NT-proBNP level measured at baseline and at the midterm follow-up had prognostic value in the patients with HF, irrespective of the development of LVRR. Ten (10%) patients experienced relapsed HF after LVRR during the follow-up and their mean LVEF was 38±6%. Patients who had relapsed HF after the midterm follow-up of LVRR used β-blockers less frequently than did the other patients (50.0% vs. 83.9%; P=0.018). Continued use of a β-blocker was also associated with a better long-term prognosis regardless of LVRR and the midterm NT-proBNP level, suggesting that continued treatment with neurohormonal blockers may be needed even after normalization of LV function and LVRR.
Study Limitations
First, this study was an observational review of a single tertiary center registry with relatively small numbers, especially for the subgroup analysis in the patients with LVRR. Second, 62 of 329 study patients were not evaluated at the midterm follow-up and 14 patients died or underwent HTx before the midterm evaluation. These limitations may have produced a selection bias, especially in the estimation of the incidence and predictors of LVRR, even though the study patients evaluated for LVRR had similar clinical and laboratory characteristics as the entire sample. Midterm follow-up was evaluated over a relatively wide range of time points, which were 6-24 months after initial evaluation. And it was performed relatively earlier in patients with LVRR because short-term reevaluations with echocardiography were usually not indicated if LVRR is confirmed. However, there are still possibilities of misclassification bias in the cases without LVRR, especially if the midterm evaluation was performed within 1 year after the initial evaluation. We did not include volumetric measures to evaluate LVRR because of the lack of data in the HF database. Cardiac magnetic resonance (CMR) imaging could have provided more precise information for evaluating volumetric changes. However, because most patients with NIDCM generally have diffuse global LV dysfunction without regional wall motion abnormalities, the calculated LVEF and LVEDD index might be a representative estimate of systolic function. Future study using CMR imaging is needed to confirm our results. In our study, NIDCM was defined based on functional and structural changes by echocardiography without genetic analysis, and the study results cannot be generalized to patients with NIDCM with a genetic or hereditary predisposition. Lastly, although the continuous use of β-blocker in the patients with LVRR was related to fewer cases of HF relapse at long-term followup, this also may be biased by the fact that it might have been less frequently prescribed by the attending physician for the clinically worse or intolerant patients.
Conclusions
LVRR was evident in approximately one-third of the patients with NIDCM at the midterm follow-up during tailored pharmacological treatment. Because LVRR and the midterm NTproBNP level were independent predictors of long-term clinical events, a follow-up strategy that uses both cardiac imaging (to evaluate LVRR for structural reserve) and neurohormonal Adjusted covariates include male sex, age, SBP, prolongation of QRS duration, log NT-proBNP at baseline, LVEF, serum creatinine, serum sodium and use of β-blocker. HR, hazard ratio; HTx, heart transplantation. Other abbreviations as in Tables 1,3 .
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status (NT-proBNP level for functional reserve) may give more reliable information about the long-term prognosis of patients with NIDCM. HF may relapse even after LVRR occurs, especially in patients not taking β-blockers, and our results suggest that maintenance with a neurohormonal blocking agent may be prudent in this population. Further multicenter, prospective studies with a large population of patients with NIDCM may be needed to evaluate relapsed HF after LVRR and its characteristics.
